Selective agonists of beta-adrenergic type 3 receptors (BAR3) for the treatment of nephrogenic diabetes insipidus

The invention consists of a method to activate cyclic AMP (cAMP)-mediated intracellular response in renal cells by triggering the beta-3 subtype adrenergic receptor (BAR3).

Settore:

Life sciences

Research Institution:

Università di Pisa

Publication number:

WO2016046763A1

Technologies, Systems, Applications:

New drugs development,
Biotechnologies

Technological Priority:

Biotechnologies for health,
Biomedical, pharmaceutical, pharmacological technologies
Pubblicato il:
Torna in cima alla pagina